Research programme: neuronal nicotinic receptor agonists - AbbVie
Alternative Names: A-366833; A-582941; A-844606; A-85380; A-859261; A-867744; A-870022; A-880006; A-988056Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Azetidines; Indoles; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cognition-disorders in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 23 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie